Table 4.
Plasma pharmacokinetic parameters of ABN401 in beagle dogs following intravenous (IV) and oral (PO) administration of 1, 5, and 10 mg/kg body weight (mean ± SD).
| Dose (mg/kg) | T1/2 (h) | Cmax (ng/mL) | Tmax (h) | AUClast (h.ng/mL) | AUCinf (h.ng/mL) | MRTlast (h) | BA (%) |
|---|---|---|---|---|---|---|---|
| IV, 1 | 1.9 ± 0.7 | 308.1 ± 270.8 | 0.083 | 266.3 ± 104.7 | 286.8 ± 107.7 | 1.5 ± 0.7 | NA |
| PO, 1 | 9.4 ± 3.2 | 8.0 ± 3.8 | 1.3 ± 0.6 | 75.4 ± 42.0 | 96.2 ± 40.7 | 7.6 ± 2.5 | 28.3 ± 15.8 |
| PO, 5 | 7.6 ± 4.5 | 50.8 ± 12.4 | 1.5 ± 0.7 | 408.7 ± 23.0 | 455.8 ± 28.5 | 8.6 ± 2.7 | 30.7 ± 1.7 |
| PO, 5 * | 4.9 ± 0.9 | 60.3 ± 29.1 | 2.0 ± 0.0 | 408.8 ± 201.3 | 425.4 ± 217.8 | 6.4 ± 0.7 | 30.7 ± 15.1 |
| PO, 10 | 7.7 ± 5.8 | 52.5 ± 13.5 | 2.0 ± 0.0 | 302.2 ± 72.0 | 424.4 ± 186.2 | 6.3 ± 3.4 | 11.3 ± 2.7 |
* without microcrystalline cellulose (MCC), NA: not applicable